Protective function of StAR in amyloid-β accumulated hippocampal neurotoxicity and neurosteroidogenesis: Mechanistic insights into Alzheimer's disease

Manna, Pulak R.; Kshirsagar, Sudhir; Pradeepkiran, Jangampalli Adi; Rawat, Priyanka; Reddy, Arubala P.; Reddy, P. Hemachandra

doi:10.1016/j.bbadis.2023.166738

Cited by 4 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neurosteroids gradually decrease with age due to the accumulation of Aβ precursor protein (APP) in the brain. Significant changes in steroid hormone production have been observed in AD patients [ 50 , 51 ], as have down-regulated steroid hormones in the stool of APP/PS1 mice. Additionally, a previous study showed that medications enhance memory impairment by connecting anti-apoptotic pathways and altering the expression of genes linked to neuroactive ligand–receptor interactions [ 52 ].…”

Section: Discussionmentioning

confidence: 99%

Ginkgo biloba Extract Drives Gut Flora and Microbial Metabolism Variation in a Mouse Model of Alzheimer’s Disease

Yu,

Xing,

Gao

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a complex neurodegenerative disease. Numerous investigations have demonstrated that medications that regulate the “brain–gut” axis can ameliorate disease symptoms of AD. Studies have shown that Ginkgo biloba extract (EGb) is involved in intestinal metabolism to meet the goal of illness treatment. EGb is currently utilized extensively in the clinical prevention and treatment of cardiovascular and cerebrovascular diseases. However, the regulatory effect of EGb on intestinal flora and its metabolites in AD pathology remains largely speculative. In this study, the Morris water maze test showed a significant improvement of spatial memory in the AD mouse model (APP/PS1 mice) after EGb treatment. We next confirmed the positive effects of EGb on the gut flora and metabolites of APP/PS1 mice and further showed that EGb treatment reshaped the disturbed gut microbiome, in particular by reducing the Firmicutes/Bacteroides ratio and increasing the abundance of Bacteroidetes, Uroviricota, Streptophyta, and Spirochaetes. Meanwhile, a non-targeted metabolomics analysis showed that EGb treatment significantly reversed the dysfunction of the microbial metabolic phenotype by altering Limosilactobacillus and Parvibacte, with 300 differential metabolites modulated (131 up-regulated, 169 down-regulated). Our findings highlight the significant regulatory impact of EGb on intestinal microflora and microbial metabolism in AD mice models and provide a potential therapeutic strategy for AD.

show abstract

Section: Discussionmentioning

confidence: 99%